Ongoing clinical trials are targeted against several tumors, including prostate stem cell antigen (PSCA)-CAR-T cells against advanced prostate cancer, IL13Ra2-CAR T cells and epidermal growth factor receptor variant III (EGFRvIII)-CAR-T cells against advanced glioblastoma, glypican 3 (GPC3)-CAR-T cells against hepatocellular carcinoma (HCC), CD70-CAR-T cells against renal cell carcinoma (RCC), GD2-CAR-T cells against neuroblastoma, and mesothelin (MSLN)-CAR-T cells against MSLN-positive solid tumors (e.g., ovarian, breast, lung, and pancreatic cancer). Here, MSLN is linked to hepatocellular carcinoma.